SHANGHAI, CHINA -- (MARKET WIRE) -- May 09, 2007 -- SinoBiomed Inc. ("SinoBiomed", "the Company") (OTCBB: SOBM) is pleased to announce that the Chinese State Food and Drug Administration (SFDA) has recertified the recombinant human interferon production plant of Shanghai Wanxing Bio-pharmaceuticals Co. Ltd. (SinoBiomed's 82-percent owned subsidiary) as a Good Manufacturing Practice (GMP) facility.
